Urinary retention with venlafaxine-haloperidol combination.
Benazzi
F
F
D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D016055:Urinary Retention / Q000139:chemically induced*; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride; D006220:Haloperidol